INTERVENTION 1:	Intervention	0
Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)	Intervention	1
doxorubicin	CHEBI:28748,BAO:0000639	0-11
cyclophosphamide	CHEBI:4026	14-30
t	CHEBI:36371,BAO:0001260	47-48
t	CHEBI:36371,BAO:0001260	60-61
AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.	Intervention	2
x	LABO:0000148	3-4
x	LABO:0000148	10-11
x	LABO:0000148	115-116
doxorubicin	CHEBI:28748,BAO:0000639	8-19
cyclophosphamide	CHEBI:4026	64-80
hour	UO:0000032	134-138
day	UO:0000033	154-157
INTERVENTION 2:	Intervention	3
Docetaxel + Doxorubicin and Cyclophosphamide (TAC)	Intervention	4
doxorubicin	CHEBI:28748,BAO:0000639	12-23
cyclophosphamide	CHEBI:4026	28-44
TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.	Intervention	5
x	LABO:0000148	4-5
x	LABO:0000148	16-17
x	LABO:0000148	96-97
x	LABO:0000148	235-236
x	LABO:0000148	292-293
hour	UO:0000032	34-38
day	UO:0000033	54-57
day	UO:0000033	170-173
doxorubicin	CHEBI:28748,BAO:0000639	94-105
doxorubicin	CHEBI:28748,BAO:0000639	233-244
cyclophosphamide	CHEBI:4026	134-150
cyclophosphamide	CHEBI:4026	257-273
Inclusion Criteria :	Eligibility	0
Histologically proven breast cancer. Interval between definitive surgery that includes axillary lymph node dissection and registration is less than or equal to 60 days. A central pathology review may be performed post randomization for confirmation of diagnosis and molecular studies.	Eligibility	1
breast cancer	DOID:1612	22-35
surgery	OAE:0000067	65-72
lymph	UBERON:0002391	96-101
central	HP:0030645	171-178
Definitive surgical treatment must be either mastectomy, or breast conserving surgery with axillary lymph node dissection for operable breast cancer (T1-3, Clinical N0-1, M0). Margins of resected specimen from definitive surgery must be histologically free of invasive adenocarcinoma and Ductal Carcinoma In Situ (DCIS). Lobular carcinoma in-situ does not count as a positive margin.	Eligibility	2
breast	UBERON:0000310	60-66
breast	UBERON:0000310	135-141
surgery	OAE:0000067	78-85
surgery	OAE:0000067	221-228
lymph	UBERON:0002391	100-105
breast cancer	DOID:1612	135-148
adenocarcinoma	DOID:299	269-283
ductal carcinoma in situ	HP:0030075,DOID:0060074	288-312
carcinoma	HP:0030731,DOID:305	274-283
carcinoma	HP:0030731,DOID:305	295-304
carcinoma	HP:0030731,DOID:305	329-338
Histologic examination of the tumor: Invasive adenocarcinoma with at least one axillary lymph node (pN1) showing evidence of tumor among a minimum of six resected lymph nodes.	Eligibility	3
adenocarcinoma	DOID:299	46-60
lymph	UBERON:0002391	88-93
lymph	UBERON:0002391	163-168
Tumor must show negative HER2 neu proto-oncogene overexpression by FISH (Fluorescence In Situ Hybridization). Confirmation of non overexpression will be centrally assessed by authorized BCIRG (Breast Cancer International Research Group) laboratories prior to randomization.	Eligibility	4
breast cancer	DOID:1612	193-206
group	CHEBI:24433	230-235
Estrogen and/or progesterone receptor analysis performed on the primary tumor prior to randomization. Results must be known at the time of randomization.(Note: Patients whose tumor is estrogen receptor negative with progesterone receptor status unknown or undetermined, must have the progesterone receptor assayed in order to determine hormonal receptor status. Patients whose tumor is progesterone receptor negative with estrogen receptor status unknown or undetermined, must have the estrogen receptor assayed in order to determine hormonal receptor status).	Eligibility	5
estrogen	CHEBI:50114,BAO:0000760	0-8
estrogen	CHEBI:50114,BAO:0000760	184-192
estrogen	CHEBI:50114,BAO:0000760	422-430
estrogen	CHEBI:50114,BAO:0000760	486-494
progesterone	CHEBI:17026	16-28
progesterone	CHEBI:17026	216-228
progesterone	CHEBI:17026	284-296
progesterone	CHEBI:17026	386-398
receptor	BAO:0000281	29-37
receptor	BAO:0000281	193-201
receptor	BAO:0000281	229-237
receptor	BAO:0000281	297-305
receptor	BAO:0000281	345-353
receptor	BAO:0000281	399-407
receptor	BAO:0000281	431-439
receptor	BAO:0000281	495-503
receptor	BAO:0000281	543-551
time	PATO:0000165	131-135
Karnofsky Performance status index > 80%.	Eligibility	6
Normal cardiac function must be confirmed by LVEF (Lef Ventricular Ejection Fraction) i.e. MUGA (Multi Gated Acquisition) scan or echocardiography and ECG within 3 months prior to registration. LVEF result must be above or equal to the lower limit of normal for the institution. The ECG results must be within normal limits or show no significant abnormalities.	Eligibility	7
function	BAO:0003117,BFO:0000034	15-23
ejection fraction	CMO:0000180	67-84
result	BAO:0000179	199-205
result	BAO:0000179	287-293
Laboratory requirements: (within 14 days prior to registration)	Eligibility	8
Hematology:	Eligibility	9
Neutrophils > or = 2.0 x 10^9/L	Eligibility	10
x	LABO:0000148	23-24
Platelets > or = 100 x 10^9/L	Eligibility	11
x	LABO:0000148	21-22
Hemoglobin > or = 10 g/dL	Eligibility	12
hemoglobin	CHEBI:35143	0-10
Hepatic function:	Eligibility	13
function	BAO:0003117,BFO:0000034	8-16
Total bilirubin < or = 1 UNL (Upper Normal Limit)	Eligibility	14
ASAT (Aspartate Amino Transferase) and ALAT (Alanine Amino Transferase) < or = 2.5 UNL	Eligibility	15
aspartate	CHEBI:29995	6-15
transferase	BAO:0000292	22-33
transferase	BAO:0000292	59-70
alanine	CHEBI:16449	45-52
Alkaline phosphatase < or = 5 UNL	Eligibility	16
phosphatase	GO:0016791,BAO:0000295	9-20
Patients with ASAT and/or ALAT > 1.5 x UNL associated with alkaline phosphatase > 2.5 x UNL are not eligible for the study.	Eligibility	17
x	LABO:0000148	37-38
x	LABO:0000148	86-87
phosphatase	GO:0016791,BAO:0000295	68-79
Renal function:	Eligibility	18
function	BAO:0003117,BFO:0000034	6-14
Creatinine < or = 175 µmol/L (2 mg/dL);	Eligibility	19
creatinine	CHEBI:16737	0-10
If limit reached, the calculated creatinine clearance should be > or = 60mL/min.	Eligibility	20
creatinine clearance	CMO:0000765	33-53
Complete staging work-up within 3 months prior to registration. All patients will have contralateral mammography, chest X-ray (Posteroanterior and lateral) and/or CT scan and/or MRI (Magnetic Resonance Imaging), abdominal ultrasound and/or CT scan (computerized tomography) and/or MRI, and bone scan. In case of positive bone scan, bone X-ray is mandatory to rule out the possibility of non-metastatic hot spots. Other tests may be performed as clinically indicated.	Eligibility	21
chest	UBERON:0001443	114-119
lateral	HP:0025275	93-100
lateral	HP:0025275	147-154
ct	BAO:0002125	163-165
ct	BAO:0002125	240-242
tomography	BAO:0002525	262-272
Negative pregnancy test (urine or serum) within 7 days prior to registration for all women of childbearing potential.	Eligibility	22
urine	UBERON:0001088	25-30
Exclusion Criteria :	Eligibility	23
Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, genetherapy , chemotherapy).	Eligibility	24
breast cancer	DOID:1612	38-51
Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy.	Eligibility	25
anthracycline	CHEBI:48120	6-19
paclitaxel	CHEBI:45863	40-50
Prior radiation therapy for breast cancer.	Eligibility	26
breast cancer	DOID:1612	28-41
Bilateral invasive breast cancer.	Eligibility	27
bilateral	HP:0012832	0-9
breast cancer	DOID:1612	19-32
Pregnant, or lactating patients. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment (chemotherapy and tamoxifen therapy) and must have negative urine or serum pregnancy test within 7 days prior to registration.	Eligibility	28
tamoxifen	CHEBI:41774	169-178
urine	UBERON:0001088	211-216
Any T4 or N2 or known N3 or M1 breast cancer.	Eligibility	29
m1	CHEBI:34826	28-30
breast cancer	DOID:1612	31-44
Pre-existing motor or sensory neurotoxicity of a severity > grade 2 by NCI-CTC (National Cancer Institute - Common Toxicity Criteria), version 2.0.	Eligibility	30
severity	HP:0012824	49-57
cancer	DOID:162	89-95
Other serious illness or medical condition:	Eligibility	31
condition	PDRO:0000129	33-42
congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrhythmias	Eligibility	32
congestive heart failure	HP:0001635,DOID:6000	0-24
angina pectoris	HP:0001681	37-52
history	BFO:0000182	63-70
myocardial infarction	HP:0001658,DOID:5844	74-95
year	UO:0000036	105-109
hypertension	HP:0000822,DOID:10763	141-153
history of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent	Eligibility	33
history	BFO:0000182	0-7
dementia	HP:0000726,DOID:1307	90-98
active uncontrolled infection	Eligibility	34
active	PATO:0002354	0-6
active peptic ulcer, unstable diabetes mellitus	Eligibility	35
active	PATO:0002354	0-6
peptic ulcer	HP:0004398	7-19
diabetes mellitus	HP:0000819,DOID:9351	30-47
Past or current history of neoplasm other than breast carcinoma, except for:	Eligibility	36
history	BFO:0000182	16-23
neoplasm	HP:0002664,DOID:14566	27-35
breast carcinoma	HP:0003002,DOID:3459	47-63
curatively treated non-melanoma skin cancer	Eligibility	37
skin cancer	DOID:4159	32-43
carcinoma in situ of the cervix	Eligibility	38
carcinoma	HP:0030731,DOID:305	0-9
other cancer curatively treated and with no evidence of disease for at least 10 years	Eligibility	39
cancer	DOID:162	6-12
disease	DOID:4,OGMS:0000031	56-63
ipsilateral ductal carcinoma in-situ (DCIS) of the breast	Eligibility	40
carcinoma	HP:0030731,DOID:305	19-28
breast	UBERON:0000310	51-57
lobular carcinoma in-situ (LCIS) of the breast	Eligibility	41
carcinoma	HP:0030731,DOID:305	8-17
breast	UBERON:0000310	40-46
Chronic treatment with corticosteroids unless initiated > 6 months prior to study entry and at low dose (< 20 mg methylprednisolone or equivalent).	Eligibility	42
chronic	HP:0011010	0-7
Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment should be stopped before study entry.	Eligibility	43
Definite contraindications for the use of corticosteroids.	Eligibility	44
Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.	Eligibility	45
drug	CHEBI:23888	45-49
drug	CHEBI:23888	130-134
Concurrent treatment with any other anti-cancer therapy.	Eligibility	46
Current therapy with any hormonal agent such as raloxifene, tamoxifen or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention. Patients must have discontinued these agents prior to randomization.	Eligibility	47
raloxifene	CHEBI:8772	48-58
tamoxifen	CHEBI:41774	60-69
estrogen	CHEBI:50114,BAO:0000760	89-97
receptor	BAO:0000281	98-106
osteoporosis	HP:0000939,DOID:11476	138-150
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.	Eligibility	48
patient	HADO:0000008,OAE:0001817	82-89
Outcome Measurement:	Results	0
Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival)	Results	1
second	UO:0000010	42-48
cancer	DOID:162	57-63
death	OAE:0000632	68-73
The primary event is the local, regional or metastatic relapse or the date of second primary cancer or death from any cause (whichever occurs first). The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.	Results	2
second	UO:0000010	78-84
cancer	DOID:162	93-99
death	OAE:0000632	103-108
efficacy	BAO:0000656	162-170
time	PATO:0000165	200-204
Time frame: Median follow-up 65 months	Results	3
time	PATO:0000165	0-4
median	BAO:0002174	12-18
Results 1:	Results	4
Arm/Group Title: Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)	Results	5
doxorubicin	CHEBI:28748,BAO:0000639	17-28
cyclophosphamide	CHEBI:4026	31-47
t	CHEBI:36371,BAO:0001260	10-11
t	CHEBI:36371,BAO:0001260	12-13
t	CHEBI:36371,BAO:0001260	64-65
t	CHEBI:36371,BAO:0001260	77-78
Arm/Group Description: AC x 4: Doxorubicin 60 mg/m  as an IV bolus in combination with cyclophosphamide 600 mg/m  as IV followed by docetaxel 100 mg/m  as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.	Results	6
x	LABO:0000148	26-27
x	LABO:0000148	33-34
x	LABO:0000148	138-139
doxorubicin	CHEBI:28748,BAO:0000639	31-42
cyclophosphamide	CHEBI:4026	87-103
hour	UO:0000032	157-161
day	UO:0000033	177-180
Overall Number of Participants Analyzed: 1649	Results	7
Measure Type: Number	Results	8
Unit of Measure: Participants  356	Results	9
Results 2:	Results	10
Arm/Group Title: Docetaxel + Doxorubicin and Cyclophosphamide (TAC)	Results	11
doxorubicin	CHEBI:28748,BAO:0000639	29-40
cyclophosphamide	CHEBI:4026	45-61
Arm/Group Description: TAC x 6 : Docetaxel 75 mg/m  as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m  as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.	Results	12
x	LABO:0000148	27-28
x	LABO:0000148	39-40
x	LABO:0000148	119-120
x	LABO:0000148	258-259
x	LABO:0000148	315-316
hour	UO:0000032	57-61
day	UO:0000033	77-80
day	UO:0000033	193-196
doxorubicin	CHEBI:28748,BAO:0000639	117-128
doxorubicin	CHEBI:28748,BAO:0000639	256-267
cyclophosphamide	CHEBI:4026	157-173
cyclophosphamide	CHEBI:4026	280-296
Overall Number of Participants Analyzed: 1649	Results	13
Measure Type: Number	Results	14
Unit of Measure: Participants  352	Results	15
Adverse Events 1:	Adverse Events	0
Total: 331/1634 (20.26%)	Adverse Events	1
Anemia 3/1634 (0.18%)	Adverse Events	2
anemia	HP:0001903,DOID:2355	0-6
Coagulation disorders 1/1634 (0.06%)	Adverse Events	3
coagulation	GO:0050817	0-11
Hemorrhage Vaginal 1/1634 (0.06%)	Adverse Events	4
Leukopenia 18/1634 (1.10%)	Adverse Events	5
leukopenia	HP:0001882,DOID:615	0-10
Lymphadenopathy 0/1634 (0.00%)	Adverse Events	6
lymphadenopathy	HP:0002716	0-15
Lymphedema 0/1634 (0.00%)	Adverse Events	7
lymphedema	HP:0001004,DOID:4977	0-10
Pancytopenia 0/1634 (0.00%)	Adverse Events	8
pancytopenia	HP:0001876,DOID:12450	0-12
Thrombocytopenia 0/1634 (0.00%)	Adverse Events	9
thrombocytopenia	HP:0001873,DOID:1588	0-16
Arrhythmia 3/1634 (0.18%)	Adverse Events	10
arrhythmia	HP:0011675	0-10
Arrhythmia Ventricular 0/1634 (0.00%)	Adverse Events	11
arrhythmia	HP:0011675	0-10
Cardiomyopathy 1/1634 (0.06%)	Adverse Events	12
cardiomyopathy	HP:0001638,DOID:0050700	0-14
Adverse Events 2:	Adverse Events	13
Total: 520/1635 (31.80%)	Adverse Events	14
Anemia 5/1635 (0.31%)	Adverse Events	15
anemia	HP:0001903,DOID:2355	0-6
Coagulation disorders 0/1635 (0.00%)	Adverse Events	16
coagulation	GO:0050817	0-11
Hemorrhage Vaginal 0/1635 (0.00%)	Adverse Events	17
Leukopenia 56/1635 (3.43%)	Adverse Events	18
leukopenia	HP:0001882,DOID:615	0-10
Lymphadenopathy 1/1635 (0.06%)	Adverse Events	19
lymphadenopathy	HP:0002716	0-15
Lymphedema 2/1635 (0.12%)	Adverse Events	20
lymphedema	HP:0001004,DOID:4977	0-10
Pancytopenia 1/1635 (0.06%)	Adverse Events	21
pancytopenia	HP:0001876,DOID:12450	0-12
Thrombocytopenia 1/1635 (0.06%)	Adverse Events	22
thrombocytopenia	HP:0001873,DOID:1588	0-16
Arrhythmia 3/1635 (0.18%)	Adverse Events	23
arrhythmia	HP:0011675	0-10
Arrhythmia Ventricular 1/1635 (0.06%)	Adverse Events	24
arrhythmia	HP:0011675	0-10
Cardiomyopathy 0/1635 (0.00%)	Adverse Events	25
cardiomyopathy	HP:0001638,DOID:0050700	0-14
